Interpares Biomedince is creating a portfolio of diagnostic assays to inform immunotherapy treatment selection in patients with metastatic solid tumors. Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma and non-small cell lung cancer with several other indications showing encouraging results. The success of this new class of drugs has led to a rapid expansion of clinical trials to determine the efficacy of combination therapy and several new classes of immunotherapies. Physicians will have to choose between a number of potentially effective treatments. Interpares' suite of assays will provide actionable information to help physicians determine the best treatment for each patient. The assays currently in the pipeline address both efficacy and safety to allow physicians and patients to understand the risk-benefit of specific treatment regimens.